pSivida has completed enrolling first US patient in investigator-sponsored clinical trial of its injectable sustained release insert.
pSivida president and CEO Ashton said the trial will study the use of injectable micro-inserts to treat posterior uveitis, a frequently blinding disease.
"These same inserts have recently been approved in several EU countries for the treatment of chronic Diabetic Macular Edema and will be marketed there by our partner Alimera Sciences," Ashton added.
"We are now independently developing the same devices for use in posterior uveitis."
The insert, a tiny tube that is about the size of an eyelash, is placed in the back of the eye through the use of a fine gauge needle.
The insert contains the steroid fluocinolone acetonide that is released at a consistent rate over a period of approximately 36 months.
